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Extracellular proteolysis mediates tissue homeostasis. In cancer, altered proteolysis leads to 
unregulated tumor growth, tissue remodeling, inflammation, tissue invasion, and metastasis. The 
matrix metalloproteinases (MMPs) represent the most prominent family of proteinases associ-
ated with tumorigenesis. Recent technological developments have markedly advanced our 
understanding of MMPs as modulators of the tumor microenvironment. In addition to their role in 
extracellular matrix turnover and cancer cell migration, MMPs regulate signaling pathways that 
control cell growth, inflammation, or angiogenesis and may even work in a nonproteolytic manner. 
These aspects of MMP function are reorienting our approaches to cancer therapy.Introduction
Cancer originates from mutations in genes that regulate 
essential pathways of cell function leading to uncontrolled 
outgrowth of tissue cells (Hanahan and Weinberg, 2000). The 
resulting tumors are complex structures of malignant cancer 
cells embedded in vasculature and surrounded by a dynamic 
tumor stroma consisting of various nonmalignant cells, such as 
fibroblasts and myeloid cells. The milieu of the tumor microen-
vironment is akin to the inflammatory response in a healing 
wound, which promotes angiogenesis, turnover of the extra-
cellular matrix (ECM), and tumor cell motility (Coussens and 
Werb, 2002). Understanding the molecular mechanisms of this 
complex interplay between malignant cancer cells and the sur-
rounding nonmalignant stroma represents one of the major 
challenges in cancer research.
Mounting evidence supports the view that extracellular pro-
teinases, such as the matrix metalloproteinases (MMPs), medi-
ate many of the changes in the microenvironment during tumor 
progression. These enzymes regulate a variety of physiological 
processes and signaling events, and thus they represent key 
players in the molecular communication between tumor and 
stroma. Here, we review the recent advances in our under-
standing of MMP-driven regulation of the tumor microenviron-
ment. Regarding the failure of MMP inhibitors as targets for 
anticancer therapy in clinical trials, we critically discuss the new 
insights into the functions of these extracellular proteinases in 
cancer, which, depending on the circumstances, may either 
suppress or promote tumorigenesis, or even act independently 
of their proteolytic activity.
Characteristics of the MMP Family
MMPs are a family of zinc-dependent endopeptidases first 
described almost half a century ago (Gross and Lapiere, 1962). 
They play a crucial role in various physiological processes 
including tissue remodeling and organ development (Page-
McCaw et al., 2007), in the regulation of inflammatory processes 52 Cell 141, April 2, 2010 ©2010 Elsevier Inc.(Parks et al., 2004), and in diseases such as cancer (Egeblad 
and Werb, 2002). The 23 MMPs expressed in humans are cat-
egorized by their architectural features. The general structural 
blueprint of MMPs shows three domains that are common to 
almost all MMPs, the pro-peptide, the catalytic domain, and 
the hemopexin-like C-terminal domain that is linked to the cat-
alytic domain via a flexible hinge region (Figure 1A). MMPs are 
initially expressed in an enzymatically inactive state due to the 
interaction of a cysteine residue of the pro-domain with the 
zinc ion of the catalytic site. Only after disruption of this inter-
action by a mechanism called cysteine switch, which is usually 
mediated by proteolytic removal of the pro-domain or chemical 
modification of the cysteine residue, does the enzyme become 
proteolytically active. The pro-domain contains a consensus 
sequence and requires proteolytic cleavage by convertases, 
which, depending on the sequences, occurs intracellularly by 
furin or extracellularly by other MMPs or serine proteinases 
such as plasmin (Sternlicht and Werb, 2001).
Closely related to the MMPs are the so-called ADAM (a dis-
integrin and metalloproteinase) and ADAMTS (a disintegrin 
and metalloproteinase with thrombospondin motifs) families 
of metzincin proteinases. ADAMs fulfill a broad spectrum of 
functions with roles in fertilization, development, and cancer 
(Edwards et al., 2008). Most ADAMs are membrane-anchored 
and function in the pericellular space. Although all of them 
have a metalloproteinase domain, only about half of them 
exhibit proteolytic activity, indicating that ADAMs function by 
shedding interaction partners or by mediating the biological 
roles in a nonproteolytic manner. The ADAMTS enzymes have 
a protease domain, an adjacent disintegrin domain, and one 
or more thrombospondin domains and are generally secreted 
and soluble. They play roles in ECM assembly, ovulation, and 
cancer. The role of these other metzincin proteinases in cancer 
has recently been extensively discussed elsewhere (Murphy, 
2008). This Review will only highlight selected examples of 
their effects on the tumor microenvironment.
The function of MMPs in vivo depends on the local balance 
between them and their physiological inhibitors. Substantial 
energy resources of the human body are allocated for the preven-
tion of unregulated extracellular proteolysis by MMPs and other 
proteinases. For example, high concentrations of the proteinase 
inhibitors α2-macroglobulin (α2-MG), α1-proteinase inhibitor 
(α1-PI), and α1-chymotrypsin (α1-CT) are produced in the liver and 
released into the plasma, where these molecules efficiently bind to 
the active site of a variety of proteinases (reviewed in Woessner and 
Nagase, 2000). The resulting proteinase-inhibitor complexes are 
then recognized by a scavenger receptor and swiftly engulfed by 
macrophages. The most important physiological inhibitors of MMP 
function are the tissue inhibitors of metalloproteinases (TIMPs), 
which are also commonly expressed in tumor sites (Deryugina and 
Quigley, 2006). TIMP-1, -2, -3, and 4 form 1:1 stochiometric com-
plexes with active MMPs leading to inhibition of proteolytic activity. 
Similar to MMPs, the proteolytic ADAM and ADAMTS family mem-
bers are inhibited by specific TIMPs (Murphy, 2008).
The expression of metalloproteinases and their inhibitors in 
the tumor microenvironment is quite diverse. Although cancer 
cells from various tissues can express members of the MMP and ADAM families as well as TIMPs, the major source of these 
proteinases is from stromal cells infiltrating the tumor (Egeblad 
and Werb, 2002). The different types of stromal cells produce 
a specific set of proteinases and proteinase inhibitors (Figure 
1B), which are released into the extracellular space and spe-
cifically alter the milieu around the tumor. The cellular source 
of MMPs can therefore have important consequences on their 
function and activity; for example, neutrophil-derived MMP-9, 
which does not have a bound TIMP-1 molecule, is more readily 
activatable (Ardi et al., 2007).
Regulation of MMP Activity
The complexity of the tumor microenvironment allows for a 
variety of regulatory cascades that determine the functions of 
the diverse MMPs expressed. Proteolytic activity of MMPs can 
be regulated at different levels: gene expression, compartmen-
talization, conversion from zymogen to active enzyme, and, 
finally, the presence of specific inhibitors. When judging the 
pathophysiological relevance of increased expression of pro-
teinases in tumor tissues, the particular context is important, 
that is whether endogenous inhibitors or activating (converting) 
enzymes in the microenvironment are present.
A key step in regulating MMP activity is the conversion of 
the zymogen into an active proteolytic enzyme. There are sev-
eral proteinases that mediate MMP activation, such as plas-
min, furin, or active MMPs (Sternlicht and Werb, 2001). Once 
activated, MMP-2, -3, -7, -9, and -12 may launch a negative 
feedback signal, for example, by degrading plasminogen and 
thus interfering with plasminogen conversion to active plasmin. 
This complex regulation of MMP activity is necessary, given 
Figure 1. MMP Composition and Expression in the Stroma
(A) Matrix metalloproteinases (MMPs) are comprised of different subdomains. 
All MMPs have the “minimal domain” in common, which contains three prin-
cipal regions: an amino-terminal signal sequence (Pre) to be cleaved by the 
signal peptidase during entry into the endoplasmic reticulum, a pro-domain 
(Pro) containing a thiol-group (-SH) and a furin cleavage site, and the catalytic 
domain with a zinc-binding site (Zn2+). Interaction of the -SH group of the 
pro-domain with the zinc ion of the catalytic domain keeps the enzyme as an 
inactive zymogen. Activation of the zymogen is often mediated by intracellular 
furin-like proteinases that target the furin recognition motif (Fu) between the 
pro-domain and the catalytic domain. In addition to the minimal domain, most 
MMPs possess a hemopexin-like region, a domain composed of four repeats 
that resemble hemopexin and contain a disulfide bond (S-S) between the first 
and the last subdomain, which is linked to the catalytic domain via a flexible 
hinge region. Besides their differential domain structure, MMPs can be prin-
cipally divided into secreted (MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13, -19, 
-20, -21, -22, -27, -28) and membrane-anchored proteinases (MMP-14, -15, 
-16, -17, -23, -24, -25), the latter of which use either a transmembrane do-
main (TM) with a cytoplasmic domain (Cy) attached to it, a glycosylphosphati-
dylinositol (GPI) anchor, or an amino-terminal signal anchor (SA), which is only 
the case for MMP-23, as it is anchored in the plasma membrane. MMP-23 
also contains the unique cysteine array (CA) and an immunoglobulin (Ig)-like 
domain. The gelatinases MMP-2 and -9 show gelatin-binding repeats that 
resemble the collagen-binding type II motif of fibronectin (FN).
(B) Expression pattern of proteinases and their physiological inhibitors in non-
malignant stromal cells. Cells commonly found in the microenvironment of 
many cancers include inflammatory cells (such as neutrophils, macrophages, 
dendritic cells, lymphocytes, and mast cells), endothelial cells, fibroblasts, 
and hematopoietic progenitor cells. These cells express a plethora of pro-
teinases that are released into the extracellular space and influence multiple 
events of tumor progression. Selected examples of proteinases and endog-
enous inhibitors expressed by these cell types are shown.Cell 141, April 2, 2010 ©2010 Elsevier Inc. 53
that unhampered proteinase activity released from inflamma-
tory cells may lead to tissue damage and the perpetuation of 
the inflammatory response in chronic inflammatory diseases 
and cancer (Parks et al., 2004). An example of how this pro-
cess is controlled is shown by the observation that MMPs also 
degrade plasmin-suppressing serpin proteinase inhibitors and 
therefore promote the conversion of pro-MMPs. For example, 
MMP-3 is a potent inactivator of α2-AP (Lijnen et al., 2001), 
and several MMPs inactivate other serpins such as α1-PI and 
α1-CT and thus prolong the catalytic activity of extracellular 
proteinases that are normally inhibited by these molecules. 
A crucial interplay of MMP-9, α1-PI, and neutrophil elastase 
occurs in skin blister formation, in which MMP-9 efficiently 
degrades α1-PI, a physiological serpin inhibitor of neutrophil 
Figure 2. Proteolytic Cascades Regulate MMP Function
MMPs are synthesized as inactive zymogens that need to be activated by pro-
teolytic removal of the pro-domain (for instance, as carried out by plasmin). 
Several MMPs exert an autocrine feedback by degrading several physiologi-
cal proteinase inhibitors that inhibit proteolytic conversion of MMPs including 
α1-chymotrypsin (α1-CT), α1-proteinase inhibitor (α1-PI), and α2-antiplasmin 
(α2-AP) (1). Some pro-MMPs can also be converted by other MMPs. Selected 
examples for mutual MMP conversion are given (2). Another physiological 
inhibitor, α2-macroglobulin (α2-MG), normally inhibits MMP activity but can 
also be degraded by several MMPs, which then prolongs MMP function (3). 
Inflammatory cells frequently infiltrate the tumor microenvironment and pro-
duce large amounts of reactive oxygen species (ROS), which may promote 
MMP activation via oxidation of the pro-domain cysteine. Myeloperoxidase 
(MPO) of infiltrating neutrophil catalyzes the transformation of ROS into hy-
pochloric acid (HOCl), which may interfere with MMP activity by chemical 
modification of crucial residues of the catalytic domain (4). On the other hand, 
active MMPs may also launch a negative feedback, for instance, by degrading 
plasminogen and therefore prohibiting the conversion into MMP-activating 
plasmin (5). The complex interaction of proteinases and their inhibitors under 
physiological circumstances happens upstream of the physiological functions 
of MMPs, such as matrix remodeling, angiogenesis, cellular signaling, and 
cancer cell migration.54 Cell 141, April 2, 2010 ©2010 Elsevier Inc.elastase and other serine proteinases. This promotes elastase-
mediated matrix degradation that manifests in dermal-epider-
mal separation and blister formation in vivo (Liu et al., 2000). 
This study nicely illustrates the interaction between extracel-
lular proteinases and their endogenous inhibitors as may occur 
in normal physiological situations and in the course of disease 
(Figure 2).
The function of MMPs can also be influenced by reactive 
oxygen species (ROS). The inflammatory response at the tumor 
site creates large amounts of ROS that are produced by acti-
vated neutrophils and macrophages. These oxidants initially 
activate MMPs via oxidation of the pro-domain cysteine (Weiss 
et al., 1985) but, eventually, in combination with the enzyme 
myeloperoxidase contributed by inflammatory cells, inactivate 
MMPs by modification of amino acids of the catalytic domain 
by hypochlorous acid (Fu et al., 2003).
The localization or compartmentalization of MMPs under 
physiological conditions often dictates their biological func-
tion. Several MMPs interact with surface receptors such as 
integrins or localize to specific areas of the ECM, which poten-
tiates MMP activity by increasing their local concentration and 
also may interfere with accessibility to endogenous inhibitors 
(reviewed in Nagase et al., 2006). The binding of MMP-2 to 
integrin αvβ3 via its hemopexin domain is crucial for mesen-
chymal cell invasive activity (Rupp et al., 2008). Likewise, high 
local concentrations of active MMP-14 on the cell membrane 
of metastatic cancer cells play important roles in cell migra-
tion (Friedl and Wolf, 2008; Sabeh et al., 2004, 2009; Wolf et 
al., 2007). However, there may also be additional mechanisms 
to concentrate extracellular proteinases in specific sites in the 
microenvironment. One new example relates to neutrophilic 
granulocytes, which, upon cellular activation, spill out their 
nuclear chromatin to form so-called neutrophil extracellular 
traps (NETs), web-like structures with highly concentrated pro-
teinases such as MMP-9 and leukocyte elastase localized on 
the extracellular chromatin scaffold (Brinkmann et al., 2004). 
These NETs act primarily to fight off bacterial infections, but 
they also contribute to the pathogenesis of autoimmune dis-
eases (Kessenbrock et al., 2009). It remains to be determined 
if NETs are formed by neutrophils in the tumor microenviron-
ment, and whether these structures play a role in malignant 
diseases by compartmentalizing and localizing proteinase 
activity to certain sites in the tumor.
Mechanical forces contribute to tumor progression (Butcher 
et al., 2009), potentially by modulating proteolysis of ECM 
components. These forces may unwind the conformation of 
MMP substrate proteins, thus allowing recognition and cleav-
age by proteinases. Von Willebrand factor (VWF), a major regu-
lator of primary hemostasis and blood clotting, is secreted as 
an ultralong chain composed of hundreds of VWF monomers. 
The large size of this multimolecular complex renders it sensi-
tive to high shear forces in the blood flow that are typically 
found at sites of injury. These increased shear forces initiate 
a conformational change of the complex, namely, unfolding of 
VWF domain 2 leading to the exposition of a cleavage site tar-
geted by ADAMTS-13, which then cleaves VWF into smaller 
pieces to initiate blood clotting (Zhang et al., 2009). In a simi-
lar fashion, the ECM component fibronectin is also unfolded 
by mechanical forces in the ECM of living cells (Smith et al., 
2007). Given that fibronectin is cleaved by several MMPs, the 
mechanotransduced unfolding of fibronectin might promote 
proteolytic degradation of this MMP substrate. Tumor progres-
sion is frequently characterized by increased tissue stiffness, 
elevated interstitial fluid pressure, and altered blood flow con-
ditions (Butcher et al., 2009). Thus, it is conceivable that similar 
mechanisms involving mechanical force are regulatory factors 
for MMP function in the tumor microenvironment.
Studying MMP Function In Vivo
The physical location and the time frame of MMP enzymatic 
activity are fundamental to the physiological role of these 
enzymes in tumor progression. However, for most cancers it 
still remains rather elusive when and where these enzymes 
exhibit their proteolytic activity in the tumor microenvironment. 
An emerging noninvasive technological approach to address 
these questions utilizes the recently developed imaging probes 
based on MMP-specific activities. This may help to overcome 
a number of technical hurdles of clinical importance, such as 
the detection of early-stage tumors with increased sensitivity 
by exploiting the proteolytic activity of MMPs, the identification 
of tumors that might benefit from the use of metalloproteinase 
inhibitors (MPIs) as anticancer drugs, and the endpoint assess-
ment of the efficacy of MPI compounds to inhibit MMP activity 
in vivo. To date, imaging MMP activity has mostly depended 
on fluorescent optical imaging modalities including fluores-
cent resonance energy transfer (FRET), radiolabeled imaging 
such as positron emission tomography (PET), single pho-
ton emission computed tomography (SPECT), and magnetic 
resonance imaging (MRI) (reviewed in Scherer et al., 2008a). 
Fluorogenic MMP substrates noninvasively show that tumors 
have increased MMP activity compared to non-tumor-bearing 
animals (Littlepage et al., 2010) and can assess the efficacy of 
MPIs on MMP activity in intact tumors in vivo directly (Bremer 
et al., 2001).
Clinical imaging technologies such as PET and SPECT that 
are used for cancer diagnostics and staging in the clinic also 
can be used to detect MMP activity in vivo. For example, PET 
has been used to detect specific MMP activity in cancer using 
an 18F-labeled MMP-2 inhibitor that accumulates in the tumor 
of a breast cancer model in mice (Furumoto et al., 2003). Radi-
olabeled 123I-MMP inhibitors designed to recognize the active 
site of specific MMPs can detect MMP-2 and MMP-9 activity 
using SPECT (Schafers et al., 2004). A radiolabeled 99 mTc-anti-
MMP-14 monoclonal antibody developed as a radiolabeled 
SPECT probe in vivo detects malignant cells in rodents bearing 
breast tumors (Temma et al., 2009). Gadolinium-based para-
magnetic contrast agents that carry an MMP-sensitive probe 
become less hydrophilic upon proteolytic cleavage result-
ing in a detectable contrast change that has been used with 
MMP-2 (Jastrzebska et al., 2009). Given that MRI facilities are 
widely available in clinical centers and are commonly utilized 
for detecting tumors, this methodology has potential as a diag-
nostic tool for cancer patients.
Using higher-resolution probes, it is now possible to nar-
row down the sites in the tumor microenvironment at which 
MMPs exert their activity. For example, cell-penetrating pep-tides, which are activated by proteolysis and carry a fluores-
cent cargo that accumulates in cells that are in the vicinity of 
active MMPs (Jiang et al., 2004), have been used successfully 
to visualize MMP-2 and -9 activity in cell culture systems and 
in mouse xenograft models and show active MMPs predomi-
nantly at the interface between tumor and stroma (Olson et 
al., 2009). Fluorogenic substrates based on self-quenched 
and near-infrared FRET pairs, so-called proteolytic beacons, 
created to reduce absorption and scattering and increase tis-
sue penetration have demonstrated specific increases in MMP 
activity at the tumor’s leading edge in models of colon and 
pancreatic cancers (Scherer et al., 2008a). For example, opti-
cal imaging of MMP-7 activity in vivo using a specific near-
infrared polymer-based proteolytic beacon can detect tumors 
as small as 0.01 cm2 in mice (Scherer et al., 2008b). Moreover, 
such probes can be used to image MMP activity at subcellular 
resolution during live-cell migration in extracellular matrices in 
vitro. To this end, experiments using matrices derivatized with 
a fluorogenic probe based on the peptide sequence present in 
interstitial collagen targeted by a variety of proteases including 
MMP-2, -9, and -14 detect MMP activity predominantly at the 
leading edges of migrating tumor cells (Packard et al., 2009). 
This new type of high-resolution probe provides site-specific 
reporting of protease activity and insights into mechanisms by 
which cells migrate through extracellular matrices.
Although in vivo imaging of MMP activity is a relatively young 
field of research with many technological challenges ahead, 
it is a promising strategy, especially regarding the future of 
MPIs as anticancer drugs. Given that the majority of clinical 
trials with MPIs have failed, presumably due to treatment of 
advanced-stage tumors, imaging with sensitive MMP probes 
will help to determine the adequate time window of MMP activ-
ity, in which MPI administration is most likely to be effective. 
Further advances in noninvasive imaging of MMP activity may 
be crucial to determine these therapy options.
New Insights into the Roles of MMPs in Cancer
MMPs have been implicated in cancer for more than 40 years, 
and the notion that MMP-mediated ECM degradation leads 
to cancer cell invasion and metastasis has been a guiding 
principle in MMP research (Liotta et al., 1980). The discovery 
that inhibition of MMPs suppresses the invasive potential of 
tumors in animal studies was swiftly implemented into clinical 
trials. Yet, these failed to increase survival rate of the patients 
(Coussens et al., 2002). It is now evident that MMP function is 
more complex than initially thought, given that these enzymes 
do more than degrade physical barriers. Rather, they also 
affect multiple signaling pathways that modulate the biol-
ogy of the cell in normal physiological processes and in dis-
ease. Moreover, members of the ADAM and ADAMTS fami-
lies of proteinases, which are also targeted by inhibitors with 
broad-spectrum anti-metzincin activity, are also associated 
with tumor progression (Murphy, 2008). Although the current 
understanding is that extracellular proteolysis is mostly impli-
cated in cancer promotion, MMPs and other proteinases do 
exhibit tumor-suppressing effects in several circumstances. In 
addition, MMPs mediate a wide range of biological effects on 
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the recent insights gained on the physiological or pathological 
processes modulated by MMPs, which are likely to have sig-
nificant consequences on the tumor microenvironment.
MMPs Affect Growth Signals
Unregulated proliferation is a common feature of cancer cells. 
There are two principal ways in which the tumor achieves this 
condition: by acquiring self-sufficiency in growth-promoting 
signals or by becoming insensitive to antigrowth signals. MMPs 
may be critically involved in disrupting the balance between 
growth and antigrowth signals in the tumor microenvironment, 
as they potently influence the bioavailability or functionality of 
multiple important factors that regulate growth.
One fundamental signaling pathway with essential roles in 
tissue homeostasis is the transforming growth factor-β (TGF-β) 
pathway. TGF-β normally exerts tumor-suppressive effects by 
enforcing cytostasis and differentiation. However, as the tumor 
advances in malignant progression, the genome often accu-
mulates mutations in the TGF-β receptor system that render 
the cancer cells unresponsive to TGF-β. Moreover, its mul-
tiple effects on nonmalignant stromal cells, such as evasion 
of immune surveillance, can be exploited by the tumor and 
hence turn TGF-β into a tumor-promoting factor that leads to 
increased invasion and metastasis (Massague, 2008). Active 
TGF-β is derived from an inactive pro-form by proteolytic con-
version by furin or other proteinases, such as MMP-9, which 
is usually expressed by inflammatory cells. MMP-9 is com-
partmentalized to the cell surface by docking to the surface 
receptor CD44 and then proteolytically activates TGF-β (Yu 
and Stamenkovic, 2000). Similarly, MMP-14 and MMP-2 prote-
olytically activate TGF-β1 (Mu et al., 2002). On the other hand, 
MMP-2 and MMP-9, as well as MMP-14, indirectly modulate 
TGF-β bioactivity by cleaving the ECM component latent TGF-
β-binding protein 1 (LTBP-1), thereby solubilizing ECM-bound 
TGF-β (Dallas et al., 2002; Tatti et al., 2008). Given that tumor 
cells often acquire nonresponsiveness to TGF-β, this suggests 
that proteolytic activation of TGF-β by MMPs has tumor-pro-
moting effects by selectively driving stroma-mediated invasion 
and metastasis of the tumor.
Ligands for the epidermal growth factor receptor (EGFR) 
are potent drivers of cell proliferation and important regulators 
of tissue homeostasis. Malfunction of this system by genetic 
mutations of the molecules involved is frequently observed in 
breast cancer and other malignant diseases (Hynes and Lane, 
2005). Evidence emerging from recent studies has revealed 
a potential role of ADAM proteinases in the regulation of the 
EGFR pathway. For example, ADAM-10 triggers the release of 
soluble EGF, whereas ADAM-17 is a major converter of pro-
forms of other EGFR ligands such as TGF-α and epiregulin. 
Activation of EGFR results in the upregulation of MMP-9, which 
in turn degrades E-cadherin, a potent control element of many 
cellular functions including cell-cell adhesion and differentia-
tion. This association between EGFR, MMP-9, and E-cadherin 
may play an important role in ovarian cancer and metastasis, 
as activated EGFR and MMP-9 in these specimens colocalize 
with a region of reduced E-cadherin (Cowden Dahl et al., 2008). 
The cleavage of E-cadherin by MMPs or ADAM proteinases has 
an impact on cancer cell proliferation. Interestingly, ADAM-10 
mediates the shedding of E-cadherin, which results in β-catenin 56 Cell 141, April 2, 2010 ©2010 Elsevier Inc.translocation to the nucleus, driving cell proliferation (Maretzky 
et al., 2005). Moreover, overexpression of MMP-3 in mammary 
epithelium triggers a cascade of events including the cleavage 
of E-cadherin resulting in epithelial-mesenchymal transition 
(Lochter et al., 1997; Radisky et al., 2005). Combining an inhibi-
tor of these metalloproteinases with a dual inhibitor of EGFR 
and HER-2/neu kinases synergistically prevents the growth of 
human breast cancer xenografts (Witters et al., 2008). These 
studies provide mechanistic insight into proteolytic accelera-
tion of cell growth and suggest that specific inhibition of these 
metalloproteinases may be utilized to interfere with unregu-
lated cell growth and proliferation in many tumors.
MMPs Regulate Apoptosis
Evading programmed cell death, or apoptosis, is another strat-
egy that increases the cell number and size of tumors. Apopto-
sis is normally initiated via extracellular receptors such as the 
Fas receptors, which activate a proteolytic cascade of intracel-
lular caspases once they encounter Fas ligand, ultimately lead-
ing to the selective degradation of subcellular compartments 
and nuclear DNA. MMP function interferes with the induction 
of apoptosis in malignant cells, which may involve the cleav-
age of ligands or receptors that transduce proapoptotic sig-
nals. MMP-7 cleaves Fas ligand from the surface of doxoru-
bicin-treated cancer cells (Mitsiades et al., 2001), lowering the 
impact of chemotherapy on the tumor by abrogating apoptosis. 
Indeed, MMP-7 expression may serve as a predictive marker 
for the resistance to chemotherapy in patients with non-small 
cell lung cancer (Liu et al., 2008a). Similarly, ADAM-10 may 
suppress apoptosis induction by cytotoxic lymphocytes via the 
degradation of Fas ligand (Schulte et al., 2007), thus interfer-
ing with Fas receptor-triggered cell death of target cells. The 
interaction between MMP-7 and Fas ligand also may play a role 
in pancreatic ductal adenocarcinoma, as MMP-7 is expressed 
in human pancreatic cancer specimens and mice deficient 
in MMP-7 or carrying a nonfunctional Fas ligand mutation 
show greatly reduced metaplasia during pancreatic duct liga-
tion (Crawford et al., 2002). Moreover, proteolytic shedding 
of tumor-associated major histocompatibility complex class 
I-related proteins MICA and MICB by ADAM-17 can potently 
suppress NK cell-mediated cytotoxicity toward the cancer cells 
(Waldhauer et al., 2008) and thereby potentially interfere with 
an antitumor-directed immune response. It remains unknown 
whether MMPs can interfere in a similar manner with NK cell-
mediated tumor killing; however, the use of MMP inhibitors in 
combination with interleukin-15 succeeded in overcoming the 
resistance of small-cell lung cancer cells to NK cell killing (Le 
Maux Chansac et al., 2008). Hence, these examples suggest a 
tumor-promoting role of these metalloproteinases by blocking 
receptor-transmitted or lymphocyte-mediated apoptosis.
The Tumor Vasculature
The tumor vasculature is derived from sprouting of local blood 
vessels (angiogenesis) and circulating vasculogenic progenitor 
cells derived from the bone marrow (vasculogenesis). The new 
vessels are often irregular and leaky due to lack of the peri-
cyte cover, with the result that tumor cells can penetrate them 
more easily. As compared with blood capillaries, lymphatic 
endothelial cells have even less developed junctions with fre-
quently large interendothelial gaps and impaired basement 
membranes. The invasive margin is a critical area for stimula-
tion of angiogenesis and lymphangiogenesis in tumors, which 
contributes to tumor invasion and metastasis (Padera et al., 
2002). As discussed below, several lines of evidence support 
an important function of MMPs in angiogenic or lymphangio-
genic processes. The major MMPs involved in tumor angio-
genesis are MMP-2, -9, and -14, and to a lesser extent MMP-1 
and -7. Given that several MMPs are expressed in all tumors, it 
is now evident that each MMP can contribute to distinct vascu-
lar events in the same tumor (Littlepage et al., 2010).
MMP-9 has a distinct role in tumor angiogenesis, mainly reg-
ulating the bioavailability of vascular endothelial growth factor 
(VEGF), the most potent inducer of tumor angiogenesis and a 
major therapeutic target. MMP-9, conveyed by inflammatory 
cells, enables an angiogenic switch by making sequestered 
VEGF bioavailable for its receptor VEGFR2 in pancreatic islet 
tumors (Bergers et al., 2000). Angiogenic switching by MMP-9 
involves a complex interplay of interconnected factors. In a 
mouse model of glioblastoma, the hypoxia inducible factor-1α 
(HIF-1α) induces recruitment of CD45-positive bone marrow-
derived cells, as well as endothelial and pericyte progenitor 
cells, to promote neovascularization. MMP-9 activity provided 
by these CD45-positive myeloid cells is essential and suffi-
cient for the angiogenic switch by increasing VEGF bioavail-
ability. This process induces angiogenesis but also regulates 
tumor cell invasiveness. Interestingly, VEGF prevents tumor 
cell migration along blood vessels, but it promotes perivascu-
lar tumor cell infiltration into the brain parenchyma (Du et al., 
2008). This action of VEGF as a brake on perivascular tumor 
cell migration is surprising. In addition, the direct cleavage of 
matrix-bound VEGF by MMP-3, -7, -9, or -16 results in modified 
VEGF molecules with altered bioavailability, which changes the 
vascular patterning of tumors in vivo (Lee et al., 2005).
In addition to its role in regulating angiogenesis, MMP-9 is 
also implicated in vasculogenesis. Tumors transplanted into 
tissue irradiated to prevent angiogenesis are unable to grow 
in MMP-9-deficient mice. However, tumor growth is restored 
by transplanting CD11b-positive myeloid cells from the bone 
marrow of MMP-9-sufficient mice, suggesting that MMP-9 
is required for tumor vasculogenesis (Ahn and Brown, 2008). 
MMP-9 could therefore be an important target for adjunct ther-
apy to enhance the response of tumors to radiotherapy.
A special role is attributed to MMP-9 delivered by neutro-
philic granulocytes. In contrast to other cell types, neutrophil-
derived pro-MMP-9 is not complexed with TIMP-1 and there-
fore is more readily activated to drive tumor angiogenesis (Ardi 
et al., 2007). The angiogenic function of neutrophil MMP-9 
requires both its active site and hemopexin domain and acti-
vates the basic fibroblast growth factor 2 (FGF-2) pathway (Ardi 
et al., 2009). This highlights the important effects of proteinase 
inhibitors on the function of MMPs and shows that MMPs pro-
duced by different cell types may function in different ways. 
The release of TIMP-1-free MMP-9 may be an important facet 
in the pro-angiogenic effects triggered by tumor-infiltrating 
neutrophils. Indeed, elevated numbers of neutrophils present 
in patients with myxofibrosarcoma correlate with microves-
sel density in the tumor (Mentzel et al., 2001), and depleting 
neutrophils in a mouse model of pancreatic cancer markedly reduces angiogenic switching in dysplasias (Nozawa et al., 
2006). These findings support an important role of infiltrating 
neutrophils in the induction of tumor angiogenesis.
The degradation of ECM components and other extracellular 
molecules may generate fragments with new bioactivities that 
inhibit angiogenesis (Ribatti, 2009). For example, biologically 
active endostatin is generated via cleavage of type XVIII col-
lagen by MMP-3, -7, -9, -13, and -20 (Heljasvaara et al., 2005). 
Moreover, the degradation of collagen IVα3 by MMP-9 results 
in the generation of the monomeric NC1 domain, called tum-
statin, a potent suppressor of angiogenesis. This manifests in 
pathological vascularization and increased tumor growth in 
MMP-9-deficient mice (Hamano et al., 2003). The degradation 
of plasminogen by MMP-2, -9, and -12 can produce signifi-
cant amounts of angiostatin, a cleavage product with antian-
giogenic function (Cornelius et al., 1998; Patterson and Sang, 
1997). Angiostatin production by MMP-12 may explain the sup-
pressive effects of this MMP on outgrowth of lung metastases 
(Houghton et al., 2006a). Taken together, MMPs can generate 
both angiogenesis-inhibiting as well as -promoting signals. 
Depending on the time frame of MMP expression and the 
availability of substrates, the effects of MMPs on angiogenesis 
might be diverse.
MMPs also regulate vascular stability and permeability. 
MMPs, particularly MMP-14, appear to mediate the vascular 
response to tissue injury and tumor progression though activa-
tion of TGF-β (Sounni et al., 2010). Use of MPIs or TGF-β sig-
naling inhibitors potentially could improve patient care as they 
may improve delivery of imaging agents or therapeutic tumor 
tissues.
Lymphangiogenesis plays an important role in tumor biology, 
given that it is directly linked with the formation of lymphatic 
metastases. MMPs certainly have a general impact on lymp-
hangiogenesis as supported by the use of broad-spectrum 
MMP inhibitors (Nakamura et al., 2004). However, only a few 
reports directly link MMPs to the formation of new lymphatic 
vessels. The modulation of VEGF bioavailability by MMPs, 
especially by MMP-9, may also affect lymphangiogenesis and, 
in turn, promotes dissemination of metastases into the lymph. 
The most direct proof for MMP involvement in lymphangiogen-
esis has come from experiments modeling lymphangiogenesis 
in a three-dimensional culture system using mouse thoracic 
duct fragments embedded in a collagen gel in which lumen-
containing lymphatic capillaries form (Bruyere et al., 2008). 
Increased expression of MMP-1, MMP-2 (Langenskiold et al., 
2005) and MMP-3 (Islekel et al., 2007) is linked with lymphatic 
invasion and lymph node metastases. Inhibition of MMP-2, -9, 
and -14 attenuates both angiogenesis and lymphangiogen-
esis and reduces lymph node metastasis (Nakamura et al., 
2004). The lymphatic vasculature, but not aortic vasculature, is 
impaired by targeted deletion of MMP-2 (Bruyere et al., 2008). 
Future studies are needed to clarify the specific pathways 
affected by MMPs in the regulation of lymphangiogenesis.
Adipocyte Regulation Affects Tumor Progression
Adipocytes are a prominent part of the tumor stroma and con-
tribute to cancer progression. Unquestionably, there are con-
sequences for the local paracrine crosstalk between the tumor 
cells and adipocytes. White adipose tissue functions in energy Cell 141, April 2, 2010 ©2010 Elsevier Inc. 57
storage and is an endocrine organ made up of adipocytes, var-
ious stromal cells, resident and infiltrating immune cells, and 
an extensive endothelial network. Adipose secretory products, 
collectively referred to as adipokines, have been identified as 
contributors to the negative consequences of adipose tissue 
expansion in cancer, cardiovascular disease, and diabetes 
(Rutkowski et al., 2009). Moreover, adipokines such as leptin, 
regulate the expression and activation of MMPs; for example, 
leptin induces the MMP-13 production in glioma cells leading 
to increased migration and tumor invasion (Yeh et al., 2009). 
Human adipose tissue-derived stem cells cocultured with can-
cer cells produce CCL5, which, in turn, promotes breast can-
cer cell invasion associated with MMP-9 activity (Pinilla et al., 
2009).
Recent reports link MMPs or TIMPs to the interplay between 
adipose tissue and the epithelium and subsequently to cancer 
transformation. MMPs affect the development of the adipose 
tissue, which, in turn, may affect the epithelium. MMPs, espe-
cially MMP-3, determine the rate of adipocyte differentiation 
during mammary gland remodeling during post-lactational 
involution, when programmed cell death of the secretory epi-
thelium takes place concomitant with the repopulation of the 
mammary fat pad with adipocytes. Fibroblastic adipogenic 
progenitor cells express very low levels of MMPs or TIMPs. The 
transcription of a number of MMP and TIMP mRNAs (MMP-2, 
-3, -13, and -14 and TIMP-1, -2, and -3) is induced in com-
mitted preadipocytes, and differentiated adipocytes express 
activated MMP-2. During involution, mammary glands from 
transgenic mice that overexpress the tissue inhibitor of met-
alloproteinases, TIMP-1, or mice carrying a targeted mutation 
in MMP-3 show accelerated differentiation and hypertrophy of 
adipocytes (Alexander et al., 2001). MMP-14 also contributes 
to the coordination of adipocyte differentiation, as the absence 
of MMP-14 aborts white adipose tissue development result-
ing in lipodystrophic null mice (Chun et al., 2006). This defect 
in MMP-14 null adipocytes only becomes evident when the 
cells are surrounded by a three-dimensional (3D) ECM, but not 
in a 2D culture system. This suggests that MMP-14 acts as a 
3D-specific modulator of adipogenesis by proteolytically regu-
lating pericellular collagen rigidity.
Recent findings have identified a new member of the adipo-
cyte “secretome” that functions to enhance MMP-2 activity. 
Wdnm1-like (a distant member of the whey acidic protein/four-
disulfide core [WAP/4-DSC] family, which is a differentiation-
dependent gene in white and brown adipogenesis) may play a 
role in remodeling of the extracellular milieu in adipogenesis, 
as well as in tumor microenvironments where adipocytes are 
key stromal components (Wu and Smas, 2008).
To date, the only MMP induced by adipose tissue that 
directly affects cancer progression is MMP-11. MMP-11 is 
expressed in adipose tissue as the tumor invades the sur-
rounding environment and negatively regulates adipogenesis 
by reducing preadipocyte differentiation and reversing mature 
adipocyte differentiation. Adipocyte dedifferentiation leads to 
the accumulation of nonmalignant peritumoral fibroblast-like 
cells, which favor cancer cell survival and tumor progression. 
This MMP-11-mediated bidirectional crosstalk between invad-
ing cancer cells and adjacent adipocytes/preadipocytes high-58 Cell 141, April 2, 2010 ©2010 Elsevier Inc.lights its central role during tumor desmoplasia and represents 
a molecular link between obesity and cancer (Motrescu and 
Rio, 2008).
Initiation of Neoplastic Progression
The initial process of tumor invasion shares many characteris-
tics with the epithelial-mesenchymal transition (EMT) program 
during developmental processes including loss of cell-cell 
adhesion and increased cellular mobility (Kalluri and Weinberg, 
2009). Overexpression of several MMPs, including MMP-3, 
-7, and -14 results in carcinoma formation (reviewed in Ege-
blad and Werb, 2002). A plausible mechanism is suggested 
by experiments showing that overexpression of MMP-3, a 
component of the tumor microenvironment, causes EMT and 
induces genomic instability in cultured mammary epithelial 
cells leading to all stages of neoplastic progression, malignant 
transformation, and mammary carcinomas in transgenic mice 
(Lochter et al., 1997; Sternlicht et al., 1999). These effects are 
linked with the expression of an alternative splice product of 
Rac1 that subsequently induces the generation of reactive oxy-
gen species by mitochondria, oxidative DNA damage, and the 
expression of EMT-related transcription factor Snail (Radisky 
et al., 2005).
Tissue Invasion and Metastasis
The lethal outcome of the vast majority of all cancers is due to 
the dissemination of metastatic tumor cells and the outgrowth 
of secondary tumors at distant sites. The initiation of metasta-
sis involves the invasion of the tumor into the peripheral tissue 
leading to intravasation of cancer cells into blood or lymphatic 
vessels from where they disseminate into secondary organs. 
Invasion and metastasis require the crossing of several physi-
cal barriers, such as the endothelial basement membrane. 
As detailed above, MMPs may account for the pathological, 
metastasis-prone vasculature often found in a growing tumor. 
Metastatic tumor cells can then enter the circulation and 
spread out over the body. Recent findings suggest that meta-
static tumor cells specifically localize to receptive sites, called 
premetastatic niches, in a complex interplay with inflammatory 
cells and hematopoietic progenitor cells (Kaplan et al., 2005).
An interesting mechanism of MMP-mediated signal trans-
duction linked with increased metastasis is observed in the 
presence of MMP-1. The proteinase-activated receptors 
(PARs), a set of G protein-coupled receptors with distinct func-
tions in thrombosis and inflammation, can affect tumor inva-
sion by inducing cancer cell migration upon proteolytic cleav-
age of the receptor. PAR-1 expression is increased in a number 
of cancers including breast, colon, and lung. A study using 
a xenograft model of breast carcinoma cells demonstrates a 
critical role for MMP-1, derived from tumor-infiltrating fibro-
blasts, in the cleavage of PAR-1, which appears to drive can-
cer cell migration and invasive behavior of the tumor (Boire et 
al., 2005). This exemplifies an important role of stroma-derived 
proteinases in the progression of tumorigenesis, carried out by 
specific signal transduction on cancer cells.
Bone is one of most common sites for metastasis, often 
leading to mortality. MMPs expressed at the interface between 
tumor and stromal cells play an important role in osteolysis and 
dissemination into bone tissue. MMP-7 expressed by osteo-
clasts at the tumor-bone interface triggers osteolysis and sub-
Figure 3. Multiple Functions of MMPs in the 
Tumor Microenvironment
Tumor progression and metastasis involve dif-
ferent stages, all of which can be modulated by 
MMPs and other extracellular proteinases. MMPs 
are mainly provided by nonmalignant, infiltrating 
stromal cells such as neutrophils, macrophages, 
or endothelial cells. Selected examples of protei-
nases and their target substrates in each of these 
steps are given in numbered boxes. Tissue inva-
sion of the tumor (1) and cancer cell intravasation 
into blood vessels (2) require extracellular matrix 
(ECM) remodeling and downregulation of cellular 
adhesion. MMPs, ADAMs, and other proteinases 
such as cathepsins (Cat)-B, -K, and -L are impli-
cated in the turnover of ECM components, but 
they also regulate cancer cell migration, for ex-
ample by cleaving proteinase-activated receptor 
(PAR)-1 or by degrading cell surface molecules 
that mediate cellular adhesion, such as CD44 
or E-cadherin. The egress of metastatic tumor 
cells into the circulation is often directly accom-
panied by tumor-associated macrophages and 
may exploit proteolytic functions that mediate 
leukocyte migration across the endothelium and 
the endothelial basement membrane (EBM) under 
physiological conditions (2). Tumors are highly 
vascularized tissues and the formation of new 
blood vessels (angiogenesis; 3) can be triggered 
by the release of vascular endothelial growth fac-
tor (VEGF), which is mainly facilitated by MMP-2 
and -9. Moreover, MMPs may also regulate angio-
genesis by the generation of angiostatin-like peptides through the cleavage of plasminogen (Plg). MMPs are potent regulators of inflammation (4), thus they 
are critically involved in the recruitment of inflammatory cells to the tumor microenvironment, for example by converting TNF-α or interleukin-8 (IL-8). They 
also generate chemotactic peptides such as PGP through the degradation of collagen (col) and form chemotactic gradients by cleaving the ECM component 
syndecan to release soluble gradients of CXCL1/KC, a potent neutrophil-attracting chemokine. Some MMPs exert anti-inflammatory function, for example by 
degrading monocyte chemotactic protein (MCP3/CCL7). Metastasis results in the dissemination of malignant cells to secondary sites distant to the primary 
tumor. Recent findings indicate that these distant sites may be primed for metastasis by inflammatory cells and hematopoietic progenitor cells (HPCs) that 
locate to these sites to form a so-called premetastatic niche (5). MMP-9 and MMP-2 are involved in this process most likely by releasing factors such as VEGF 
and Kit ligand (Kit-L), which recruits HPCs from the bone marrow (BM).sequent bone metastasis in a rodent model of prostate cancer 
(Lynch et al., 2005). The target of MMP-7 is the TNF family mem-
ber RANKL (Receptor Activator for Nuclear Factor κB Ligand). 
Normally, RANKL is expressed on activated osteoblasts, so 
that the close contact between osteoclasts and osteoblasts 
enables binding of RANKL to its receptor RANK on osteoclast 
progenitors leading to osteoclast differentiation. In this con-
text, cleavage by MMP-7 releases an active form of RANKL 
that promotes osteoclast activation without osteoblasts in the 
close proximity. A similar effect has recently been elucidated 
for MMP-1 and ADAMTS-1 by knocking down these proteases 
in a highly bone-metastatic clone of the human breast cancer 
cell line MDA-MB-231 (Lu et al., 2009). Further analyses reveal 
that ADAMTS-1 and MMP-1 proteolytically engage EGF-like 
ligands, resulting in activation of the RANKL pathway, which 
in turn promotes osteolysis and metastasis to the bone. These 
findings support the identification of the MMP-1 gene as part 
of the multigenic program that mediates bone metastasis of 
breast cancer cells (Kang et al., 2003). Taken together, these 
proteinases could serve as therapeutic targets to prevent 
metastasis to the bone in breast or prostate cancer.
Although there is a wide range of biological functions of 
MMPs in cancer, a central role is the degradation and remodel-
ing of the ECM, paving the way through the peripheral tissue 
for invasion and metastasis. Recent studies using high-reso-
lution multimodal microscopy have further corroborated the importance of ECM remodeling by MMP-14-driven pericellular 
proteolysis, which potently patterns the tissue to facilitate sin-
gle-cell and finally collective-cell migration and invasion (Wolf 
et al., 2007). A number of ECM degrading proteolytic enzymes, 
such as MMP-1, -2, -13, and -14 and cathepsins B, K, and L 
have been implicated in this process; however MMP-14 may be 
critical and rate limiting in collagen turnover (Friedl and Wolf, 
2008; Sabeh et al., 2004). A striking observation is that meta-
static cancer cells can switch from a protease-dependent to a 
protease-independent invasion program by utilizing an amoe-
boid migration mode (Wolf et al., 2007). It remains a subject 
of ongoing debate whether the amoeboid migration mode is 
only relevant under in vitro conditions when the surrounding 
collagen network is devoid of covalent crosslinks (Sabeh et al., 
2009).
Mounting evidence from in vivo analyses support the view 
that motility of metastatic cancer cells and their egress into the 
circulation occur in close cooperation with tumor-associated 
macrophages (Wyckoff et al., 2004; see Review by B. Qian and 
J.W. Pollard on page 39 of this issue). Proteolytic degradation 
of the endothelial basement membrane and other matrix com-
ponents has long been associated with immune cell extrava-
sation during inflammatory conditions and may be crucial for 
intravasation of tumor cells into the circulation. Indeed, mac-
rophage-derived MMP-2 and -9 are important mediators of 
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immune encephalitis, which involves degradation of the ECM 
component dystroglycan (Agrawal et al., 2006). This suggests 
that MMPs delivered by tumor-associated macrophages might 
contribute to intravasation of cancer cells into the blood stream. 
However, the significance of myeloid cell-derived MMPs in 
the intra- and extravasation of metastatic cancer cells needs 
further examination, for example by high-resolution intravital 
microscopy using specific MMP activity-based probes.
Metastatic Niche Formation
Certain organs such as lung, liver, or bone are the preferen-
tial sites for the formation of metastases. Metastasis not only 
depends on features of the cancer cells disseminating from 
the primary tumor but also requires the formation of a recep-
tive environment, a metastatic niche, that is specifically suited 
for the engraftment of tumor cells at the distant organ. It is 
likely that MMPs and other proteinases are crucially involved in 
the formation of a metastatic niche (Figure 3). Soluble factors 
released from the primary tumor appear to trigger the formation 
of a metastatic niche that is induced initially by the expression 
of embryonic-type fibronectin, which is most likely produced 
by fibroblasts at these sites (Kaplan et al., 2005). This event 
takes place before disseminated tumor cells are detectable 
at these distant organs, hence the authors name this process 
the formation of a “premetastatic niche.” Increased fibronectin 
production at these sites allows for the infiltration of VEGFR1-
positive, bone marrow-derived progenitor cells, which then 
establish a metastasis-supporting microenvironment.
Recent studies have shed more light on the factors released 
by the primary tumor that initiate the metastatic niche. VEGF-
A, TGF-β, and tumor necrosis factor-α (TNF-α) produced by 
tumor cells trigger the expression of S100 chemokines by lung 
endothelium, which, in turn, mediate the directed migration 
of myeloid cells to these distant sites (Hiratsuka et al., 2006). 
Why these factors trigger the expression of chemokines at loci 
within specific tissues remains to be investigated. In a follow-up 
study, the authors further identified serum amyloid A3 (SAA3) 
as a potential upstream regulator of S100 chemokines during 
this process. Interestingly, the formation of a premetastatic 
niche depends on the inflammatory response by infiltrating 
myeloid cells. It appears that SAA3 triggers toll-like receptor 
4 (TLR4) signaling in lung-infiltrating myeloid cells leading to 
activation of the nuclear factor κB (NF-κB) pathway (Hiratsuka 
et al., 2008). Activation of the NF-κB pathway triggers substan-
tial production of MMPs by stromal cells (Bond et al., 1998), 
which then potentially contributes to the microenvironmental 
changes by degrading ECM and releasing growth factors.
Indeed, MMP-9 turns out to be critical for the formation of 
the metastatic niche (Kaplan et al., 2005), which is most likely 
linked with its ability to liberate VEGF and thereby support 
angiogenesis (Bergers et al., 2000). MMP-9 releases soluble 
Kit-ligand to recruit stem and progenitor cells from the bone 
marrow (Heissig et al., 2002), which may be of particular signifi-
cance in this context, given that the niche-forming progenitor 
cells express c-Kit (Kaplan et al., 2005).
Lysyl oxidase (LOX) secreted by hypoxic breast cancer cells 
may contribute to setting up metastatic sites because it cross-
links proteins including collagen IV in basement membrane 
structures. This results in the recruitment of myeloid cells to 60 Cell 141, April 2, 2010 ©2010 Elsevier Inc.these sites (Erler et al., 2009), possibly owing to altered tissue 
stiffness (Levental et al., 2009). These invading myeloid cells 
release MMPs, which degrade collagen fibers and release 
peptides that may guide the homing of bone marrow-derived 
cells and metastasizing tumor cells to these sites. Interest-
ingly, the production of MMPs, namely MMP-3 and -10, is 
upregulated together with the angiogenic modulator angiopoi-
etin 2 in premetastatic lung tissue even before myeloid cells 
are recruited to these sites (Huang et al., 2009). Given that in 
vivo RNA interference of MMP-3, MMP-10, and angiopoietin 
2 markedly attenuates vascular permeability and infiltration of 
myeloid cells into the lung, it is likely that these three factors 
synergize in the destabilization of the pulmonary vasculature, 
thus promoting metastasis. These findings imply an important 
role of extracellular proteolysis in premetastatic niche gen-
eration. Although future studies are needed to elucidate the 
critical pathways modulated by these proteinases, it appears 
that the action of MMPs in this instance critically involves the 
modulation of inflammatory processes.
MMPs Orchestrate Inflammation in Cancer
There is increasing evidence implicating MMPs as major regula-
tors of innate and acquired immunity. The process of inflamma-
tion and production of cytokines by immune cells are in many 
ways linked to cancer progression (Lin and Karin, 2007). In this 
section, we discuss how MMPs modulate the function of cytok-
ines and chemokines and what consequences this immunoreg-
ulatory function may have on the tumor microenvironment.
There is strong evidence from studies in knockout mice that 
MMPs play an important role in acute as well as chronic inflam-
mation (Parks et al., 2004). One of the most important proinflam-
matory cytokines is TNF-α, which is expressed as a membrane-
bound precursor (pro-TNF-α) on a variety of cells including 
macrophages and T cells. Conversion of pro-TNF-α into the sol-
uble cytokinetic form requires proteolytic cleavage by ADAM-17, 
also known as TNF converting enzyme (TACE), or by several 
MMPs including MMP-1, -2, -3, -9, -12, -14, -15, and -17 (Manicone 
and McGuire, 2008). Although ADAM-17 is most likely the major 
TNF-α-generating convertase, MMPs may be important TNF-α-
converting mediators in specific physiological or pathological cir-
cumstances, as described for MMP-7 in the regulation of inflam-
mation during resorption of herniated discs (Haro et al., 2000). 
Many tumors produce abundant TNF-α, and it promotes cancer 
cell survival in an NF-κB-dependent manner (Luo et al., 2004), 
suggesting that the conversion of TNF-α by MMPs and ADAM-17 
might be a crucial step in this tumor-promoting cascade.
A number of studies have shown the proteolytic alteration 
of chemokines by MMPs. Several members of the CCL/mono-
cyte chemoattractant protein (MCP) family of chemokines are 
cleaved by MMPs, which specifically renders them into non-
activating receptor antagonists with inflammation-dampening 
effects (McQuibban et al., 2002). For instance, CCL8/MCP-2 
is processed by MMP-1 and MMP-3. Indeed, the proteolytic 
cleavage of CCL8 can counteract the antitumor capacity of 
this chemokine in a melanoma model (Struyf et al., 2009). 
This study shows that proteolytic cleavage of a chemokine 
can have great impact in a clinically relevant setting of tumor 
development.
MMP-8, -9, and -12 also modulate the bioactivity of CXCL11/
I-TAC, a potent Th1 lymphocyte-attracting chemokine (Cox et 
al., 2008). Although MMP-mediated N-terminal truncation of 
CXCL11 leads to inactivation of the chemokine and creates a 
potent receptor antagonist, further C-terminal cleavage abol-
ishes the antagonist function and removes heparin-binding 
capacity of CXCL11, thereby solubilizing the chemokine from 
the ECM. These findings implicate myeloid cell-derived MMPs 
in the regulation of T cell responses, which may have important 
consequences on the adaptive antitumor immune response. 
CXCR7, the chemokine receptor for CXCL11, is also expressed 
on many tumor cells and can transmit growth- and survival-
promoting signals (Burns et al., 2006). Modulation of CXCL11 by 
MMPs might therefore reduce the antitumor immune response 
and thus have direct consequences on tumor growth.
The classical function of MMPs, the degradation of ECM, 
may have secondary effects on the immune system, as some 
of the proteolytic fragments of MMP-processed ECM compo-
nents exert chemotactic properties. Likewise, macrophage 
elastase MMP-12 produces neutrophil-attracting peptides by 
degrading elastin (Houghton et al., 2006b). Moreover, ECM 
breakdown during airway inflammation generates the frag-
ment N-acetyl Pro-Gly-Pro (PGP), a tripeptide with chemotac-
tic activity through activation of CXC chemokine receptors on 
neutrophilic granulocytes (Weathington et al., 2006). MMP-8 is 
involved in the generation of chemotactic PGP and thus regu-
lates neutrophil recruitment to the sites of inflammation (Rocks 
et al., 2008), which may cause a delay in the wound-healing 
response and increase inflammation over time, as observed 
previously in MMP-8-deficient mice (Gutierrez-Fernandez et 
al., 2007). MMP-8 contributed by neutrophils also has a tumor-
suppressing role in a mouse model of carcinogen-induced 
skin cancer (Balbin et al., 2003). The defect in the resolution of 
inflammation and the tendency to develop chronic inflammation 
in the absence of MMP-8 in mice explain how loss-of-function 
mutations of MMP-8 contribute mechanistically to increased 
susceptibility of skin adenocarcinoma and melanoma forma-
tion in humans (Palavalli et al., 2009). However, expression of 
MMP-8 in tumor cells also tightens their adhesion to the ECM 
and thereby may directly suppress metastatic behavior (Gutier-
rez-Fernandez et al., 2008). Thus, interference with the tumor-
suppressing function of MMP-8 should be regarded as one of 
the unwanted effects of broad-spectrum MMP inhibitors.
The infiltration of neutrophils in the tumor microenviron-
ment often correlates with poor prognosis (de Visser et al., 
2006). Neutrophils, like other inflammatory cells, sense the 
concentration gradient of chemokines such as CXCL1/KC, a 
homolog of CXCL8 in mice, which forms complexes with the 
heparan sulfate proteoglycan syndecan-1 on interstitial cell 
surfaces. MMP-7 indirectly modulates the bioactivity of CXCL1 
by cleaving syndecan-1 from cell surfaces and thereby releas-
ing chemotactic complexes of syndecan-1 and CXCL1 (Li et 
al., 2002). This efficiently leads to the generation of a concen-
tration gradient of soluble chemotactic CXCL1-syndecan-1 
complexes. In a comparable manner, N-terminal processing 
of neutrophil-attracting CXCL8/interleukin-8 (IL-8) by MMP-9 
leads to 10-fold increased chemotactic activity on neutrophils 
compared to full-length CXCL8 (Van den Steen et al., 2000). Therefore, MMPs orchestrate the recruitment of leukocytes 
as an essential component of tumor-associated inflammation 
(Figure 3).
Nonproteolytic Functions of MMPs
An emerging area of interest is the noncatalytic function of 
MMPs. The discovery of such functions in MMPs is not so sur-
prising, given that about half of all ADAMs show proteolytic 
capacity, whereas the other half act in a nonproteolytic manner. 
The hemopexin domain of MMPs plays an important role in the 
nonproteolytic function of MMPs. The first in vivo hint for a cru-
cial hemopexin-mediated function of MMPs was established 
with the observation that TIMP-1 and -2 bind to several MMPs 
via their hemopexin domains. Indeed, activation of MMP-2 
requires TIMP-2 that is bound to one molecule of MMP-14 via 
its catalytic domain and also is bound to pro-MMP-2 via its 
hemopexin domain. A second molecule of MMP-14 then cata-
lytically activates MMP-2 (Strongin et al., 1995).
Several members of the MMP family trigger immune or can-
cer cell migration; however, recent evidence suggests that 
they mediate chemotaxis even without using their proteolytic 
domain. Precursor forms of MMP-2 and -9 enhance cell migra-
tion in a transwell chamber assay. The hemopexin domain of 
MMP-9, but not its proteolytic activity, is necessary for MMP-
9-mediated epithelial cell migration in this assay (Dufour et al., 
2008). In this context, activation of the MAP kinase and PI3 
kinase pathways appear to be involved in this nonproteolytic 
function of MMP-9; the distinct molecular pathway as well as 
the in vivo role of this function yet remain elusive. Moreover, the 
cytoplasmic tail of MMP-14 carries out a migration-promoting 
function on macrophages, as genetic depletion of the cyto-
plasmic tail but not of the extracellular hemopexin or catalytic 
domain impairs the migration of macrophages during in vitro 
migration through Matrigel (Sakamoto and Seiki, 2009).
Clear evidence for the physiological relevance of hemopexin 
domains of MMPs has come more recently using genetic mod-
ification of one of the two Mmp genes of Drosophila melano-
gaster (Glasheen et al., 2009). These investigations reveal that, 
although the catalytic domain is required for all MMP functions, 
the hemopexin domain is specifically implicated in tissue inva-
sion during metamorphosis but not for tracheal remodeling.
A more direct nonproteolytic function has been recently elu-
cidated for MMP-12. The hemopexin domain, but not the cata-
lytic site, of MMP-12 (macrophage elastase) plays an essen-
tial role in the recently described antimicrobial function of this 
enzyme (Houghton et al., 2009). Deleting MMP-12 genetically 
in mice results in impaired bacterial clearance and increased 
mortality when infected with gram-negative and gram-positive 
bacteria. The antimicrobial properties of MMP-12 map to a 
unique four amino acid sequence within the hemopexin-like 
C-terminal domain and do not require catalytic activity of the 
enzyme. It remains to be determined whether similar nonpro-
teolytic motifs are present in other MMPs and whether these 
nonproteolytic modes of action are also implicated in cancer-
related functions of these enzymes.
Several MMPs may interact with other extracellular mol-
ecules without inducing proteolytic cleavage. MMP-14 inter-
acts with the C1q component of the complement system in Cell 141, April 2, 2010 ©2010 Elsevier Inc. 61
Figure 4. Modulation of the Tumor 
 Microenvironment by MMPs
Summary of the various processes that are modu-
lated by MMPs in the tumor microenvironment. 
The selected examples of MMPs and ADAMs pro-
mote (pro) or suppress (anti) these processes. An 
intravital microscopy image of the mammary gland 
of MMTV-PyMT mice that spontaneously develop 
mammary carcinoma was taken using a spinning 
disc inverted confocal microscope (Egeblad et al., 
2008). These mice also express enhanced cyan 
fluorescent protein (CFP) under the control of the 
actin promoter (ACTB-ECFP) to enable tumor cell 
labeling (blue) and enhanced green fluorescent 
protein (GFP) expression under the control of a c-
fms promoter (c-fms-EGFP) to label myeloid cells 
(green). These mice were injected intravenously 
with 70 kDa rhodamine-dextran to visualize blood 
vessels (red). This image illustrates the complex-
ity of the tumor microenvironment, which is largely 
influenced by nonmalignant cells, such as myel-
oid cells, all of which could be targets as well as 
sources for MMPs.a nonproteolytic, receptor-ligand manner, without inducing 
C1qr and C1qs proteinase activity, suggesting that this bind-
ing may inhibit activation of the complement proteinase cas-
cade (Rozanov et al., 2004). Further studies are yet required to 
address the biological relevance of MMP-14-mediated inhibi-
tion of the complement system in tumorigenesis. MMPs also 
bind to members of the integrin family of cell surface recep-
tors. A recent study has now linked the nonproteolytic interac-
tion of pro-MMP-1 with α2β1 integrin on neurons with MMP-1-
induced neuronal cell death in cell culture (Conant et al., 2004). 
Reduced dephosphorylation of AKT after MMP-1 incubation, 
which is inhibited by a blocking α2 integrin antibody, but not 
by administration of Batimastat, an inhibitor of MMP activity, 
suggests that integrin binding, rather than proteinase activity, 
is relevant for MMP-1-transmitted cytotoxicity. In chronic lym-
phocytic leukemia, MMP-9 promotes B cell survival in a non-
proteolytic fashion via its hemopexin domain by docking to the 
surface receptors α4β1 and CD44v, which induce intracellular 
signaling involving Lyn activation and STAT3 phosphorylation 
that prevents B cell apoptosis (Redondo-Munoz et al., 2010).
Taken together, these data indicate that we are only begin-
ning to understand nonproteolytic functions of MMPs and that 
further studies are required to clarify this principle and evalu-
ate its role under in vivo conditions. However, it is tempting to 
speculate that nonproteolytic functions of MMPs could explain 
why previous clinical trials using inhibitors of the MMP catalytic 
domains failed as anticancer therapeutics.
Conclusions and Perspectives
MMPs are associated with multiple human cancers; hence they 
were early considered as drug targets to treat cancer. The first 
drug development programs based on the notion of blocking 
MMP-mediated angiogenesis and metastasis were started about 
25 years ago and led to a number of small-molecule metallopro-
teinase inhibitor (MPI) drugs in phase III clinical trials. The effects 
of MPIs in these trials turned out to be disappointing as they 62 Cell 141, April 2, 2010 ©2010 Elsevier Inc.failed to increase the survival rate of cancer patients. Possible 
reasons for the failure of MPIs have been extensively discussed 
previously (Coussens et al., 2002). Indeed, the clinical studies 
were suboptimally designed with respect to the stage of cancer, 
so the question remains whether MPIs might have proven more 
effective when used in earlier stages of the disease.
Part of the rationale to use MPIs as anticancer drugs was to 
block interstitial migration of metastatic cancer cells. However, 
recent analyses have shown that cancer cells can switch to an 
amoeboid-like protease-independent migration mode by form-
ing actin-rich protrusions and “squeezing” through the ECM 
(Wolf et al., 2007). This would render MPIs impotent to inhibit 
the migratory behavior of metastatic tumor cells. Whether this 
alternative migration mode is actually relevant for cancer cell 
migration under in vivo conditions in the presence of a natu-
rally crosslinked collagen matrix currently remains question-
able. Mounting evidence supports a dominant role of MMP-14 
in the migration and invasion of metastatic tumor cells; hence 
MMP-14 remains a promising therapeutic target (Sabeh et al., 
2009). This would support the use of MPIs that specifically 
inhibit MMP-14 as anti-invasive drugs.
The cytostatic potential attributed to MPIs is certainly in 
keeping with the numerous studies describing MMP-medi-
ated regulation of cell growth signals, such as the activation 
of TGF-β by MMP-2, -9, and -14 (Dallas et al., 2002; Mu et al., 
2002), the proteolytic release of soluble EGFR ligands, or the 
degradation of E-cadherin by MMP-3 or -9 (Cowden Dahl et 
al., 2008; Radisky et al., 2005). Moreover, MMPs interfere with 
apoptosis induction, especially after chemotherapy, by cleav-
ing Fas ligand from the surface of cancer cells as shown for 
MMP-7 (Mitsiades et al., 2001). In the clinical trials, MPIs were 
administered to patients with advanced cancer, which was 
most likely too late to exert any beneficial effect on survival.
Interfering with the tumor vasculature is regarded as one of 
the most promising strategies to inhibit tumor growth and has 
motivated the development of drugs like Bevacizumab (Avas-
tin, anti-VEGF monoclonal antibody), which has been FDA 
approved for the treatment of metastatic cancers in combina-
tion with chemotherapy. Many studies also support a dominant 
role of MMP-9 in the angiogenic switch by regulating the bio-
availability of VEGF tumors (e.g., Bergers et al., 2000), suggest-
ing a beneficial effect of MPI on tumor angiogenesis. However, 
in other cancer models, MMP-9 generates ECM fragments like 
tumstatin, a potent suppressor of tumor vasculature formation, 
resulting in increased tumor growth in MMP-9-deficient mice 
(Hamano et al., 2003). This illustrates that one MMP can have 
opposing effects in different tumor types and highlights that 
the use of MPIs has to be carefully considered and evaluated 
for each specific kind of cancer.
Most of the initial studies utilized cancer cell lines that over-
express certain members of the MMP family (reviewed in Ege-
blad and Werb, 2002). These studies may not recapitulate the 
situation in vivo, where the major source of MMPs is nonma-
lignant stromal cells. In fact, the cellular source of each MMP 
is of high significance, as the activity of the released enzyme 
varies substantially between cell types. This should be taken 
into account when assessing the expression patterns of MMPs 
in cancer types that should be considered for treatments with 
MPIs.
Certainly, the complexity of the mode of action of MMPs has 
expanded considerably from proteinases that simply degrade 
the ECM, to specific modulators of angiogenesis as well as 
fine-tuners of cell signaling pathways and the inflammatory 
response (Figure 4). One of the major, recent advances in 
MMP research is the discovery of specific regulatory effects 
of MMPs on the stromal cells in the tumor microenvironment. 
MMPs affect adipocyte function, which is especially likely to 
be implicated in adipose-rich tumor sites such as breast. They 
also regulate the course of the inflammatory reaction in mul-
tiple ways and facilitate the recruitment of inflammatory cells 
by altering the function of chemokines and the bioavailability 
of important proinflammatory cytokines. Regarding the link 
between inflammation and cancer (Lin and Karin, 2007), the 
interference with MMP-mediated immunoregulatory functions 
could prove beneficial for cancer patients. For example, given 
that TNF-α contributes to progression of several sorts of can-
cer (Balkwill, 2009), inhibiting TNF-α activation using MPIs 
might dampen the inflammatory milieu at the tumor microen-
vironment.
Effects of MMPs on myeloid cells may well be implicated in 
the generation of the premetastatic niche. In fact, MMP-2, -3, 
and -9 have already been shown to contribute to the establish-
ment of metastasis-prone sites at tumor-distant organs (Erler 
et al., 2009; Huang et al., 2009; Kaplan et al., 2005). These 
insights argue for the use of MPIs at early stages of malignant 
disease, prior to the full initiation of tumor-associated inflam-
mation and before the soil has been primed for metastasis in 
distant organs.
The tumor-suppressing functions of these MMPs is prob-
ably another reason for the failure of broad-spectrum MPIs as 
anticancer drugs (Lopez-Otin and Matrisian, 2007). The inflam-
mation-suppressing function of MMPs accounts for increased 
incidence of cancer development in MMP-8 knockout mice 
(Balbin et al., 2003) and for the link between MMP-8 loss-of-function mutations and melanoma in humans (Palavalli et al., 
2009). Also, MMP-12 delivered by macrophages can suppress 
the growth of lung metastases, which appears to involve regu-
lation of the tumor vasculature (Houghton et al., 2006a). Apart 
from that, some MMPs carry out biological functions other 
than proteolytic, mediated by specific binding to certain target 
molecules, for instance via their hemopexin domain. Small-
molecule MMP inhibitors as used in clinical trials are certainly 
ineffective to interfere with a nonproteolytic role of MMPs.
One of the major tasks for the future is the development of 
active site-directed inhibitors or antibodies that are specific for 
single MMPs and show little or no cross-reaction with other 
MMPs (Cuniasse et al., 2005). For example, a monoclonal anti-
body raised against the catalytic domain of MMP-14 success-
fully inhibits the migration and invasion of endothelial cells in 
collagen and fibrin gels (Galvez et al., 2001). Antibodies could 
also target functional noncatalytic domains of MMPs. More-
over, MMP activity can be exploited to activate cytotoxic agents 
such as anthrax toxin to target the tumor vasculature (Liu et al., 
2008b). These agents need to be validated for specificity using 
MMP-deficient animals and rigorously tested in experimental 
cancer models. New activity-based imaging probes specific 
for MMPs will facilitate monitoring the effect of MPIs on the 
function of MMPs in vivo. The combination of these probes 
with minimal invasive imaging techniques will soon allow the 
improved endpoint assessment for the efficacy of these com-
pounds in inhibiting the target function in vivo. Imaging activity 
of specific MMPs in vivo will further advance our understand-
ing of the time frame of MMP function during the progression 
of certain tumors. Like the development of tailor-made thera-
pies and medications based on individual oncogenic pathway 
signatures in human cancers (Bild et al., 2006), expression pat-
terns of MMPs in cancer patients could facilitate a fully rational 
decision about when and in what combination MPIs and anti-
cancer drugs should be used in the future.
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